Bayer Ag Pk Stock EBITDA
Bayer AG PK fundamentals help investors to digest information that contributes to Bayer AG's financial success or failures. It also enables traders to predict the movement of Bayer Pink Sheet. The fundamental analysis module provides a way to measure Bayer AG's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bayer AG pink sheet.
Bayer |
Bayer AG PK Company EBITDA Analysis
Bayer AG's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Bayer AG EBITDA | 6.45 B |
Most of Bayer AG's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bayer AG PK is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Bayer AG PK reported earnings before interest,tax, depreciation and amortization of 6.45 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 65.42% lower than that of the firm.
Bayer EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bayer AG's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bayer AG could also be used in its relative valuation, which is a method of valuing Bayer AG by comparing valuation metrics of similar companies.Bayer AG is currently under evaluation in ebitda category among its peers.
Bayer Fundamentals
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0576 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 87.41 B | ||||
| Shares Outstanding | 3.93 B | ||||
| Shares Owned By Institutions | 0.10 % | ||||
| Price To Earning | 12.46 X | ||||
| Price To Book | 1.36 X | ||||
| Price To Sales | 1.02 X | ||||
| Revenue | 44.08 B | ||||
| Gross Profit | 27.04 B | ||||
| EBITDA | 6.45 B | ||||
| Net Income | 1000 M | ||||
| Cash And Equivalents | 9.07 B | ||||
| Cash Per Share | 2.31 X | ||||
| Total Debt | 35.55 B | ||||
| Debt To Equity | 1.08 % | ||||
| Current Ratio | 1.16 X | ||||
| Book Value Per Share | 10.50 X | ||||
| Cash Flow From Operations | 5.09 B | ||||
| Earnings Per Share | 1.28 X | ||||
| Price To Earnings To Growth | 1.31 X | ||||
| Target Price | 15.0 | ||||
| Number Of Employees | 102.3 K | ||||
| Beta | 1.17 | ||||
| Market Capitalization | 64.01 B | ||||
| Total Asset | 120.24 B | ||||
| Working Capital | 8.49 B | ||||
| Current Asset | 25.17 B | ||||
| Current Liabilities | 16.68 B | ||||
| Z Score | 0.6 | ||||
| Annual Yield | 0.03 % | ||||
| Five Year Return | 4.08 % | ||||
| Net Asset | 120.24 B | ||||
| Last Dividend Paid | 2.0 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Bayer Pink Sheet
If you are still planning to invest in Bayer AG PK check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bayer AG's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |